The True Cost of Compromise in Enzyme Selection

In today’s biotech landscape, few decisions have a bigger impact on success than enzyme choice. Enzymes drive nearly every process in molecular biology, from cloning and protein expression to gene editing and scale-up manufacturing. Yet scientists are often asked to balance performance, purity, and cost - a compromise that undermines efficiency, quality, and innovation.​

At TriAltus Bioscience, we believe compromise is unnecessary. Our proprietary CLīM (CL7/Im7 affinity purification) system proves that high performance, high purity, and low cost can coexist. We believe that true value comes from delivering all three.​

The Hidden Costs of Low Performance

When enzyme activity dips below expected levels, the consequences cascade through a project. Low-performance reagents lead to weaker yields, inconsistent data, and time-consuming reruns. A subpar enzyme might appear cheaper on paper, but in reality, each failed experiment multiplies hidden costs.

For example, laboratories working with gene cloning or CRISPR applications rely heavily on reaction efficiency. If an enzyme delivers 20% lower activity than specification, technicians often increase the concentration or repeat reactions, doubling usage cost and consuming costly reagents downstream. A small compromise in activity can quickly turn into a significant budget overrun.​

Purity, The Foundation of Reliability

Purity directly affects reproducibility. Contaminants and host proteins can introduce unwanted background signals or interfere with downstream steps. In precision applications, these reliability issues become operational risks. Regulatory concerns and batch-to-batch variability can delay timelines and increase quality control burdens, all because the original enzyme wasn’t as clean as advertised.​

Why Traditional Purification Hits a Wall

Most conventional suppliers can deliver high-purity enzymes, but the route they take to get there is inefficient. Achieving purity typically requires multiple purification steps: affinity first step, tag-removal, dialysis, ion exchange, and additional polishing. Each step consuming buffers, time, and labor. Every additional step erodes enzyme yield and adds cost.

Each purification stage can reduce total enzyme yield by 10–20%+. By the end of a five-step process, less than half of the original yield may remain. The supplier passes the cost of that inefficiency down to the customer in the form of higher per-unit pricing.​

The CLīM Advantage: Purity in One Step

TriAltus’ CLīM technology, powered by the ultra-high-affinity interaction between the CL7 tag (~16 kDa DNase variant) and Im7 inhibitor (~10 kDa), breaks that cycle. The CL7 tag expressed on the target enzyme, binds with femtomolar affinity (Kd ~10⁻¹⁴ M) to the Im7-resin, even in high-salt conditions up to 2–4 M NaCl.

This enables one-step purification: Load clarified lysate directly onto Im7 resin, wash contaminants, cleave via engineered protease site, and elute pure enzyme. The result: >95–99% purity, near-complete activity recovery, and binding capacities up to 35–60 mg/mL - all without multi-step losses.

Passing Efficiency to the Customer

Because CLīM maximizes yield and minimizes processing, TriAltus translates those gains into customer value. No paying premiums for multi-step overhead, just premium enzymes at accessible prices.

This scales seamlessly for research to production (mg-g), supporting CRISPR workflows, protein assays, and biomanufacturing with consistent results and lower cost-per-reaction. Procurement teams see direct ROI through reduced waste and faster timelines.​

TriAltus: Enzymes Without Compromise

Traditional suppliers force tradeoffs; TriAltus eliminates them. CLīM (CL7/Im7) redefines enzyme value, delivering top-tier purity, performance, and economics from a single, smarter step.

“Enzymes Without Compromise” is our commitment: No sacrifices in quality, yield, or budget. For molecular biology teams pushing boundaries, TriAltus means robust science, accelerated progress, and real savings.

Explore the TriAltus enzyme catalog.

Switching to TriAltus

For most organizations, the first step in moving to a new enzyme supplier is a structured evaluation. That typically means defining specifications, requesting a sample, and testing that enzyme in your own hands, in your own assay, under your own conditions. It’s a critical step, and also where risk, uncertainty, and internal hesitation often appear.

This is especially true when you are considering a custom enzyme or transitioning away from internal production. Evaluating a new supplier for a never-before-purified protein can feel risky. Trusting a highly specialized company that purifies enzymes in a way no one else does can seem like one more layer of uncertainty.

We understand that. And we designed our approach to directly address it.

Why Pilots Are a Bottleneck

Outsourced pilot productions are often the single biggest obstacle on the path to a long-term supply partnership. They can be costly, resource-intensive, and filled with unknowns. The standard model in the industry is “best-effort” pilots. That means you pay for a serious attempt to develop a purification strategy, but there is no guarantee that the outcome will be a spec-meeting enzyme, especially for challenging or novel targets. When pilots carry that much risk, it becomes easier to delay decisions, stay with suboptimal internal processes, or accept compromises from current suppliers.

The Pilot2Partnership™ Program: Removing the Biggest Obstacle

At TriAltus, we decided to do things differently. We believe in our CL7/Im7 purification technology and in our team strongly enough to remove the largest friction point in starting a new partnership: the pilot itself.

For projects with a clear path to long-term bulk supply and a recurring partnership, we are offering free pilot R&D through our Pilot2Partnership™ program. Instead of asking you to fund an uncertain proof-of-concept, we invest upfront:

• We take on the development risk for your enzyme purification.

• We use our platform to design and execute the pilot at no R&D fee.

• You evaluate the resulting enzyme against your specifications and assays.

If the pilot demonstrates that we can meet your needs, we transition together into a structured supply relationship with clear quality, volume, and delivery expectations. If it does not, you walk away with data and experience and not a sunk pilot budget.

Let’s Explore Your Path to Supply

Whether you are:

• Moving away from internal enzyme production

• Replacing a current external supplier

• Or scaling a promising program into sustained bulk demand

TriAltus is ready to help you evaluate a partnership in a way that respects your time, budget, and risk tolerance. Our Pilot2Partnership™ program is designed for teams who see a realistic route to ongoing bulk supply and want a more predictable, lower-friction way to get there.

Contact us to discuss your project and determine whether Pilot2Partnership™ is the right fit. Together, we can transform a high-risk pilot into the first step of a long-term enzyme supply solution — without compromise.